Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Símbolo de cotizaciónNXLIW
Nombre de la empresaNexalin Technology Inc
Fecha de salida a bolsaSep 16, 2022
Director ejecutivoMr. Mark White
Número de empleados- -
Tipo de seguridadCompany Warrant
Fin del año fiscal- -
Dirección1776 Yorktown
CiudadHOUSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal77056
Teléfono18322600222
Sitio Webhttps://nexalin.com
Símbolo de cotizaciónNXLIW
Fecha de salida a bolsaSep 16, 2022
Director ejecutivoMr. Mark White
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos